These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35293291)

  • 1. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India-An Ambi-Directional Cohort Study.
    Thomas J; Rajmohan P; Jose P; Kannan R; Jose R; Uttumadathil Gopinathan U; Raphael L; Baiju NM; Krishna S; Attokaran T; Bency A T J; Venugopal A; Sheela S; Kallempadam A; Jose L; Innah SJ; Varghese PR; George A
    Viruses; 2023 Oct; 15(11):. PubMed ID: 38005865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
    Asokan MS; Joan RF; Babji S; Dayma G; Nadukkandy P; Subrahmanyam V; Pandey A; Malagi G; Arya P; Mahajan V; Bhavikatti J; Pawar K; Thorat A; Shah P; Goud RB; Roy B; Rajukutty S; Immanuel S; Agarwal D; Saha S; Shivaraj A; Panikulam P; Shome R; Gulzar SE; Sharma AU; Naik A; Talashi S; Belekar M; Yadav R; Khude P; V M; Shivalingaiah S; Deshmukh U; Bhise C; Joshi M; Inbaraj LR; Chandrasingh S; Ghose A; Jamora C; Karumbati AS; Sundaramurthy V; Johnson A; Ramesh N; Chetan N; Parthiban C; Ahmed A; Rakshit S; Adiga V; D'souza G; Rale V; George CE; John J; Kawade A; Chaturvedi A; Raghunathan A; Dias M; Bhosale A; Raghu P; Shashidhara LS; Vyakarnam A; Bal V; Kang G; Mayor S
    Lancet Reg Health Southeast Asia; 2024 Mar; 22():100361. PubMed ID: 38482152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review.
    Das S; Kar SS; Samanta S; Banerjee J; Giri B; Dash SK
    Immunol Res; 2022 Jun; 70(3):289-315. PubMed ID: 35192185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
    Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of prior vaccination with Covishield
    Abhilash KPP; Mathiyalagan P; Krishnaraj VRK; Selvan S; Kanagarajan R; Reddy NP; Rajendiran N; Hazra D; Gunasekaran K; Moorthy M; Jasmine S; Davis JP; George T; George K; Varghese GM; Rupali P; Barney Isaac TJ; Gupta R; Pichamuthu K; Joy M; Jayaseelan L; Mathews P; Peter JV
    Vaccine; 2022 Mar; 40(13):2107-2113. PubMed ID: 35168837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
    Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
    J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran.
    Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
    Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
    Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study.
    Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M
    Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
    Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
    Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
    Vadrevu KM; Reddy S; Jogdand H; Ganneru B; Mirza N; Tripathy VN; Singh C; Khalatkar V; Prasanth S; Rai S; Ella R; Blackwelder W; Prasad S; Ella K
    Lancet Infect Dis; 2022 Sep; 22(9):1303-1312. PubMed ID: 35717995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India.
    Singh B; Seema K; Mahuli AV; Kumar A; Boipai M; Sharma AK; Kumar M; Kumar S; Chandra S; Shahi AK
    Cureus; 2023 Oct; 15(10):e47566. PubMed ID: 38021860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
    Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
    PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.